Asmaa Jan Muhammad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Asmaa Jan Muhammad has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Arooj Mohsin Alvi
Department of Pharmacy, Ibadat International University, Islamabad, Pakistan
4 shared publications - Fawad Ali Shah
Department of Pharmacology and Toxicology College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia
4 shared publications - Ikram Ullah
Associate Professor (Tenured) ,Sulaiman Bin Abdullah Aba Al-Khail-Centre for Interdisciplinary Research in Basic Sciences, International Islamic University, H-10, Islamabad 44000, Pakistan
2 shared publications - Jinxing Feng
Department of Neonatology, Shenzhen Children’s Hospital, Shenzhen, China
2 shared publications - Lina Tariq Al Kury
Department of Health Sciences, College of Natural and Health Sciences, Zayed University, Abu Dhabi 144534, United Arab Emirates
2 shared publications Shupeng Li
2 shared publications
Latest Publications
- Open Access
- 1 July 2025
- Published by Health and Research Insights in Insights-Journal of Life and Social Sciences
- Vol. 3 (4 (Social)) , 52-57
COMPARATIVE EFFICACY OF COGNITIVE BEHAVIORAL THERAPY AND PHARMACOLOGICAL TREATMENT IN GENERALIZED ANXIETY DISORDER
Background: Generalized anxiety disorder (GAD) is a prevalent psychiatric condition characterized by persistent and excessive worry, significantly impairing quality of life and daily functioning. Both cognitive behavioral therapy (CBT) and pharmacological interventions are recognized as first-line treatments; however, uncertainty remains regarding their relative long-term effectiveness and relapse prevention potential. Existing studies have yielded variable outcomes, warranting a comprehensive synthesis to guide evidence-based clinical decision-making. Objective: This systematic review aims to evaluate and compare the effectiveness of cognitive behavioral therapy versus pharmacologic treatments in reducing symptoms and preventing relapse in adult patients with generalized anxiety disorder. Methods: A systematic review was conducted following PRISMA guidelines. Databases searched included PubMed, Scopus, Web of Science, and Cochrane Library up to 2024. Randomized controlled trials and high-quality meta-analyses comparing CBT with pharmacologic treatments in adults diagnosed with GAD were included. Studies were screened using predefined inclusion and exclusion criteria, with data independently extracted and assessed for risk of bias using the Cochrane RoB 2.0 tool. A narrative synthesis was performed due to heterogeneity in outcome measures and interventions. Results: Eight studies encompassing a total of 2,643 participants were included. Both CBT and pharmacological treatments significantly reduced anxiety symptoms. While pharmacologic treatments provided faster initial symptom relief, CBT demonstrated superior long-term outcomes, including lower relapse rates and sustained symptom reduction. CBT was also associated with fewer adverse effects and better treatment adherence. Methodological quality was generally high, although heterogeneity and potential publication bias were noted. Conclusion: CBT appears to be as effective as pharmacologic treatment for GAD in the short term and offers distinct advantages in long-term management and relapse prevention. Despite the strength of current evidence, further large-scale, standardized trials are needed to validate these findings and refine treatment guidelines.
- 1 July 2025
- Published by Health and Research Insights in Insights-Journal of Life and Social Sciences
- Vol. 3 (4 (Social)) , 52-57
Open AccessCOMPARATIVE EFFICACY OF COGNITIVE BEHAVIORAL THERAPY AND PHARMACOLOGICAL TREATMENT IN GENERALIZED ANXIETY DISORDER
Background: Generalized anxiety disorder (GAD) is a prevalent psychiatric condition characterized by persistent and excessive worry, significantly impairing quality of life and daily functioning. Both cognitive behavioral therapy (CBT) and pharmacological interventions are recognized as first-line treatments; however, uncertainty remains regarding their relative long-term effectiveness and relapse prevention potential. Existing studies have yielded variable outcomes, warranting a comprehensive synthesis to guide evidence-based clinical decision-making. Objective: This systematic review aims to evaluate and compare the effectiveness of cognitive behavioral therapy versus pharmacologic treatments in reducing symptoms and preventing relapse in adult patients with generalized anxiety disorder. Methods: A systematic review was conducted following PRISMA guidelines. Databases searched included PubMed, Scopus, Web of Science, and Cochrane Library up to 2024. Randomized controlled trials and high-quality meta-analyses comparing CBT with pharmacologic treatments in adults diagnosed with GAD were included. Studies were screened using predefined inclusion and exclusion criteria, with data independently extracted and assessed for risk of bias using the Cochrane RoB 2.0 tool. A narrative synthesis was performed due to heterogeneity in outcome measures and interventions. Results: Eight studies encompassing a total of 2,643 participants were included. Both CBT and pharmacological treatments significantly reduced anxiety symptoms. While pharmacologic treatments provided faster initial symptom relief, CBT demonstrated superior long-term outcomes, including lower relapse rates and sustained symptom reduction. CBT was also associated with fewer adverse effects and better treatment adherence. Methodological quality was generally high, although heterogeneity and potential publication bias were noted. Conclusion: CBT appears to be as effective as pharmacologic treatment for GAD in the short term and offers distinct advantages in long-term management and relapse prevention. Despite the strength of current evidence, further large-scale, standardized trials are needed to validate these findings and refine treatment guidelines.
- RetractionOpen Access
- 31 October 2022
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 15, 6013-6014
1,3,4, Oxadiazole Compound A3 Provides Robust Protection Against PTZ-Induced Neuroinflammation and Oxidative Stress by Regulating Nrf2-Pathway [Retraction]
Retraction for the article 1,3,4, Oxadiazole Compound A3 Provides Robust Protection Against PTZ-Induced Neuroinflammation and Oxidative Stress by Regulating Nrf2-Pathway
- 31 October 2022
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 15, 6013-6014
RetractionOpen Access1,3,4, Oxadiazole Compound A3 Provides Robust Protection Against PTZ-Induced Neuroinflammation and Oxidative Stress by Regulating Nrf2-Pathway [Retraction]
Retraction for the article 1,3,4, Oxadiazole Compound A3 Provides Robust Protection Against PTZ-Induced Neuroinflammation and Oxidative Stress by Regulating Nrf2-Pathway
- RetractedOpen Access
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 4509204
[Retracted] Carveol Promotes Nrf2 Contribution in Depressive Disorders through an Anti‐inflammatory Mechanism
Major depressive disorder (MDD) is a progressive deteriorating mental state with a feeling of worthlessness and frequent mood swings. Several studies reported the favorable effects of natural drug substances on MMD associated oxidative stress and neuroinflammation. The present study is attempted to examine whether carveol could affect lipopolysaccharide‐ (LPS‐) induced depression, and if so, how nuclear factor E2‐related factor (Nrf2) contributed to the neuroprotective effects of carveol mechanistically. Two experimental cohorts were used using the SD rats: first to evaluate the promising dose of carveol (whether 20 mg/kg or 50 mg/kg) and secondly to determine the effect of carveol on Nrf2‐mediated antidepression. Significant neuronal alterations were noticed in the cortex and hippocampus regions in the LPS‐treated group, accompanied by elevated inflammatory cytokine levels such as tumor necrosis factor‐alpha (TNF‐α), cyclooxygenase (COX‐2), and c‐Jun N‐terminal kinase (p‐JNK). Moreover, amassing of free radicals exacerbated lipid peroxidase (LPO) and oxidative stress with a limited antioxidant capacity. Carveol (20 mg/kg) significantly ameliorated these detrimental effects by promoting the antioxidant Nrf2 gene and protein, which critically regulate the downstream antioxidant and anti‐inflammatory pathway. To further elaborate our hypothesis, we employed all‐trans retinoic acid (ATRA), an Nrf2 inhibitor, and we found that ATRA exaggerated LPS‐induced depressive‐like effects associated with elevated neuroinflammatory markers. Our results demonstrated that carveol (20 mg/kg) could activate the endogenous antioxidant Nrf2, which regulates the downstream antioxidant signaling pathway, eventually leading to amelioration of LPS‐induced neuroinflammation and neurodegeneration.
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 4509204
RetractedOpen Access[Retracted] Carveol Promotes Nrf2 Contribution in Depressive Disorders through an Anti‐inflammatory Mechanism
Major depressive disorder (MDD) is a progressive deteriorating mental state with a feeling of worthlessness and frequent mood swings. Several studies reported the favorable effects of natural drug substances on MMD associated oxidative stress and neuroinflammation. The present study is attempted to examine whether carveol could affect lipopolysaccharide‐ (LPS‐) induced depression, and if so, how nuclear factor E2‐related factor (Nrf2) contributed to the neuroprotective effects of carveol mechanistically. Two experimental cohorts were used using the SD rats: first to evaluate the promising dose of carveol (whether 20 mg/kg or 50 mg/kg) and secondly to determine the effect of carveol on Nrf2‐mediated antidepression. Significant neuronal alterations were noticed in the cortex and hippocampus regions in the LPS‐treated group, accompanied by elevated inflammatory cytokine levels such as tumor necrosis factor‐alpha (TNF‐α), cyclooxygenase (COX‐2), and c‐Jun N‐terminal kinase (p‐JNK). Moreover, amassing of free radicals exacerbated lipid peroxidase (LPO) and oxidative stress with a limited antioxidant capacity. Carveol (20 mg/kg) significantly ameliorated these detrimental effects by promoting the antioxidant Nrf2 gene and protein, which critically regulate the downstream antioxidant and anti‐inflammatory pathway. To further elaborate our hypothesis, we employed all‐trans retinoic acid (ATRA), an Nrf2 inhibitor, and we found that ATRA exaggerated LPS‐induced depressive‐like effects associated with elevated neuroinflammatory markers. Our results demonstrated that carveol (20 mg/kg) could activate the endogenous antioxidant Nrf2, which regulates the downstream antioxidant signaling pathway, eventually leading to amelioration of LPS‐induced neuroinflammation and neurodegeneration.
- RetractedOpen Access
- 1 December 2021
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 14, 7393-7409
1,3,4, Oxadiazole Compound A3 Provides Robust Protection Against PTZ-Induced Neuroinflammation and Oxidative Stress by Regulating Nrf2-Pathway
Background: Epilepsy is a common neurological disorder that is characterized by recurrent episodes of seizures. Various studies have demonstrated a direct association between oxidative stress and inflammation in several neurological disorders including epilepsy. This study aimed to investigate the neuroprotective effects of a synthetic 1,3,4, oxadiazole compound A3 against pentylenetetrazole (PTZ)-induced kindling and seizure model. Methodology: PTZ was administered in a sub-convulsive dose of 40 mg/kg for 15 days, at 48-hour intervals to male Swiss-Albino mice until animals were fully kindled. Two different doses of A3 (10 mg/kg and 30 mg/kg) were administered to find out the effective dose of A3 and to further demonstrate the relative role of nuclear factor E2-related factor (Nrf2) in the PTZ-induced kindled model. Results: Our results demonstrated a compromised antioxidant capacity associated with a low level of catalase (CAT), superoxide dismutase (SOD), glutathione (GST), and glutathione S-transferase (GSH) in the kindled group. However, the PTZ-induced group demonstrated an elevated level of lipid peroxidation (LPO) level parallel to pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), mediators as cyclooxygenase (COX-2), and nuclear factor kappa B (NFκB). Furthermore, the A3 treatment reversed these changes and overexpressed the antioxidant Nrf2 gene and its downstream HO-1. To further investigate the involvement of Nrf2, we employed an Nrf2-inhibitor, ie, all-trans retinoic acid (ATRA), that further aggravated the PTZ toxicity. Moreover, vascular endothelial growth factor (VEGF) expression was evaluated to assess the extent of BBB disruption. Conclusion: The findings of this study suggest that A3 could mediate neuroprotection possibly by activating Nrf2 dependent downregulation of inflammatory cascades.
- 1 December 2021
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 14, 7393-7409
RetractedOpen Access1,3,4, Oxadiazole Compound A3 Provides Robust Protection Against PTZ-Induced Neuroinflammation and Oxidative Stress by Regulating Nrf2-Pathway
Background: Epilepsy is a common neurological disorder that is characterized by recurrent episodes of seizures. Various studies have demonstrated a direct association between oxidative stress and inflammation in several neurological disorders including epilepsy. This study aimed to investigate the neuroprotective effects of a synthetic 1,3,4, oxadiazole compound A3 against pentylenetetrazole (PTZ)-induced kindling and seizure model. Methodology: PTZ was administered in a sub-convulsive dose of 40 mg/kg for 15 days, at 48-hour intervals to male Swiss-Albino mice until animals were fully kindled. Two different doses of A3 (10 mg/kg and 30 mg/kg) were administered to find out the effective dose of A3 and to further demonstrate the relative role of nuclear factor E2-related factor (Nrf2) in the PTZ-induced kindled model. Results: Our results demonstrated a compromised antioxidant capacity associated with a low level of catalase (CAT), superoxide dismutase (SOD), glutathione (GST), and glutathione S-transferase (GSH) in the kindled group. However, the PTZ-induced group demonstrated an elevated level of lipid peroxidation (LPO) level parallel to pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), mediators as cyclooxygenase (COX-2), and nuclear factor kappa B (NFκB). Furthermore, the A3 treatment reversed these changes and overexpressed the antioxidant Nrf2 gene and its downstream HO-1. To further investigate the involvement of Nrf2, we employed an Nrf2-inhibitor, ie, all-trans retinoic acid (ATRA), that further aggravated the PTZ toxicity. Moreover, vascular endothelial growth factor (VEGF) expression was evaluated to assess the extent of BBB disruption. Conclusion: The findings of this study suggest that A3 could mediate neuroprotection possibly by activating Nrf2 dependent downregulation of inflammatory cascades.
- Open Access
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Carveol Attenuates Seizure Severity and Neuroinflammation in Pentylenetetrazole‐Kindled Epileptic Rats by Regulating the Nrf2 Signaling Pathway
Epilepsy is a neurodegenerative brain disorder characterized by recurrent seizure attacks. Numerous studies have suggested a strong correlation between oxidative stress and neuroinflammation in several neurodegenerative disorders including epilepsy. This study is aimed at investigating the neuroprotective effects of the natural compound carveol against pentylenetetrazole‐ (PTZ‐) induced kindling and seizure model. Two different doses of carveol (10 mg/kg and 20 mg/kg) were administered to male rats to determine the effects and the effective dose of carveol and to further demonstrate the mechanism of action of nuclear factor E2‐related factor (Nrf2) in PTZ‐induced kindling model. Our results demonstrated reduced levels of innate antioxidants such as superoxide dismutase (SOD), catalase, glutathione‐S‐transferase (GST), and glutathione (GSH), associated with elevated lipid peroxidation (LPO) and inflammatory cytokines level such as tumor necrosis factor‐alpha (TNF‐α), and mediators like cyclooxygenase (COX‐2) and nuclear factor kappa B (NFκB). These detrimental effects exacerbated oxidative stress and provoked a marked neuronal alteration in the cortex and hippocampus of PTZ‐intoxicated animals that were associated with upregulated Nrf2 gene expression. Furthermore, carveol treatment positively modulated the antioxidant gene Nrf2 and its downstream target HO-1. To further investigate the role of Nrf2, an inhibitor of Nrf2 called all‐trans retinoic acid (ATRA) was used, which further exacerbated PTZ toxicity. Moreover, carveol treatment induced cholinergic system activation by mitigating acetylcholinesterase level which is further linked to attenuated neuroinflammatory cascade. The extent of blood‐brain barrier disruption was evaluated based on vascular endothelial growth factor (VEGF) expression. Taken together, our findings suggest that carveol acts as an Nrf2 activator and therefore induces downstream antioxidants and mitigates inflammatory insults through multiple pathways. This eventually alleviates PTZ‐induced neuroinflammation and neurodegeneration.
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Open AccessCarveol Attenuates Seizure Severity and Neuroinflammation in Pentylenetetrazole‐Kindled Epileptic Rats by Regulating the Nrf2 Signaling Pathway
Epilepsy is a neurodegenerative brain disorder characterized by recurrent seizure attacks. Numerous studies have suggested a strong correlation between oxidative stress and neuroinflammation in several neurodegenerative disorders including epilepsy. This study is aimed at investigating the neuroprotective effects of the natural compound carveol against pentylenetetrazole‐ (PTZ‐) induced kindling and seizure model. Two different doses of carveol (10 mg/kg and 20 mg/kg) were administered to male rats to determine the effects and the effective dose of carveol and to further demonstrate the mechanism of action of nuclear factor E2‐related factor (Nrf2) in PTZ‐induced kindling model. Our results demonstrated reduced levels of innate antioxidants such as superoxide dismutase (SOD), catalase, glutathione‐S‐transferase (GST), and glutathione (GSH), associated with elevated lipid peroxidation (LPO) and inflammatory cytokines level such as tumor necrosis factor‐alpha (TNF‐α), and mediators like cyclooxygenase (COX‐2) and nuclear factor kappa B (NFκB). These detrimental effects exacerbated oxidative stress and provoked a marked neuronal alteration in the cortex and hippocampus of PTZ‐intoxicated animals that were associated with upregulated Nrf2 gene expression. Furthermore, carveol treatment positively modulated the antioxidant gene Nrf2 and its downstream target HO-1. To further investigate the role of Nrf2, an inhibitor of Nrf2 called all‐trans retinoic acid (ATRA) was used, which further exacerbated PTZ toxicity. Moreover, carveol treatment induced cholinergic system activation by mitigating acetylcholinesterase level which is further linked to attenuated neuroinflammatory cascade. The extent of blood‐brain barrier disruption was evaluated based on vascular endothelial growth factor (VEGF) expression. Taken together, our findings suggest that carveol acts as an Nrf2 activator and therefore induces downstream antioxidants and mitigates inflammatory insults through multiple pathways. This eventually alleviates PTZ‐induced neuroinflammation and neurodegeneration.